8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Feb 20, 2026·SEC
KALA BIO, Inc.(KALA)Earnings, Financials & Key Ratios
KALA•NASDAQ
Price updated Jun 19, 2026
AboutKala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.Show more
- Revenue$0
- EBITDA-$39M+3.3%
- Net Income-$27M+29.9%
- EPS (Diluted)-3.31+52.6%
- ROE-279.18%+28.1%
KALA Key Insights
KALA BIO, Inc. (KALA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 23.7%
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 47.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KALA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KALA Price & Volume
KALA BIO, Inc. (KALA) stock price & volume — 10-year historical chart
Loading chart...
KALA Growth Metrics
KALA BIO, Inc. (KALA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM44.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM64.86%
Return on Capital
10 Years-86.95%
5 Years-102.06%
3 Years-112.65%
Last Year-172.05%
KALA Recent Earnings
KALA BIO, Inc. (KALA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.14+98.4%
$8.50
Rev
—
—
Q2 2026
Apr 15, 2026Metric
Actual
Est
EPS
$0.08+100.5%
$16.00
Rev
—
—
Q4 2025
Nov 19, 2025Metric
Actual
Est
EPS
$1.07-5.9%
$1.01
Rev
—
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$1.71+6.0%
$1.82
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.14vs $8.50+98.4% | — |
| Q2 2026 | Apr 15, 2026 | $0.08vs $16.00+100.5% | — |
| Q4 2025 | Nov 19, 2025 | $1.07vs $1.01-5.9% | — |
| Q3 2025 | Aug 8, 2025 | $1.71vs $1.82+6.0% | — |
Based on last 12 quarters of dataView full earnings history →
KALA Peer Comparison
KALA BIO, Inc. (KALA) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OCUL | 2.06B | 9.43 | -6.64 | -18.67% | -5.58% | -64.55% | 0.12 | |
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 HROW | 1.6B | 42.87 | -306.21 | 36.41% | -5.57% | -33.92% | 4.84 | |
 SGHT | 287.28M | 5.28 | -7.14 | -3.13% | -46.83% | -59.1% | 0.64 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 REPL | 841.41M | 10.19 | -3.32 | -102.69% | 0.18 | |||
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare KALA vs Peers
KALA BIO, Inc. (KALA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KALA Income Statement
KALA BIO, Inc. (KALA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 6.07M | 6.36M | 11.24M | 3.89M | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | 4.74% | 76.67% | -65.37% | -100% | - | - | - |
Cost of Goods Sold | 643K | 955K | 2.85M | 3.17M | 4.1M | 2.56M | 303K | 259K | 0 | 54K |
COGS % of Revenue | - | - | 46.89% | 49.87% | 36.45% | 65.78% | - | - | - | - |
Gross Profit | -643K▲ 0% | -955K▼ 48.5% | 3.23M▲ 437.8% | 3.19M▼ 1.1% | 7.14M▲ 124.0% | 1.33M▼ 81.4% | -303K▼ 122.7% | -259K▲ 14.5% | 0▲ 100.0% | -54K▲ 0% |
Gross Margin % | - | - | 53.11% | 50.13% | 63.55% | 34.22% | - | - | - | - |
Gross Profit Growth % | -116.5% | -48.52% | 437.8% | -1.15% | 123.99% | -81.35% | -122.75% | 14.52% | 100% | - |
Operating Expenses | 39.23M | 63.77M | 91.45M | 99.42M | 116.58M | 82.69M | 38.85M | 40.17M | 39.16M | 30.24M |
OpEx % of Revenue | - | - | 1505.6% | 1562.72% | 1037.15% | 2124.56% | - | - | - | - |
Selling, General & Admin | 10.22M | 34.48M | 64.49M | 81.07M | 105.06M | 65.03M | 20.26M | 18.34M | 23.63M | 20.78M |
SG&A % of Revenue | - | - | 1061.79% | 1274.25% | 934.71% | 1670.99% | - | - | - | - |
Research & Development | 29.01M | 29.29M | 26.96M | 18.35M | 11.52M | 17.65M | 18.59M | 21.84M | 18.78M | 12.73M |
R&D % of Revenue | - | - | 443.81% | 288.46% | 102.45% | 453.57% | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.25M | -847K |
Operating Income | -39.88M▲ 0% | -64.72M▼ 62.3% | -88.22M▼ 36.3% | -96.23M▼ 9.1% | -109.43M▼ 13.7% | -81.36M▲ 25.7% | -39.15M▲ 51.9% | -40.43M▼ 3.3% | -39.16M▲ 3.1% | -30.29M▲ 0% |
Operating Margin % | - | - | -1452.49% | -1512.59% | -973.6% | -2090.34% | - | - | - | - |
Operating Income Growth % | -22.06% | -62.31% | -36.31% | -9.08% | -13.72% | 25.66% | 51.87% | -3.27% | 3.15% | - |
EBITDA | -39.23M | -63.77M | -85.61M | -93.39M | -107.17M | -80.5M | -38.85M | -40.17M | -38.84M | -30.05M |
EBITDA Margin % | - | - | -1409.42% | -1468.01% | -953.43% | -2068.24% | - | - | - | - |
EBITDA Growth % | -21.19% | -62.54% | -34.25% | -9.1% | -14.74% | 24.89% | 51.74% | -3.41% | 3.31% | 23.1% |
D&A (Non-Cash Add-back) | 643K | 955K | 2.62M | 2.84M | 2.27M | 860K | 303K | 259K | 317K | 249K |
EBIT | -39.88M | -64.72M | -88.22M | -96.23M | -109.43M | -81.36M | -39.15M | -40.43M | -23.7M | -28.7M |
Net Interest Income | -492K | -1.63M | -6.12M | -8.1M | -8.28M | -6.6M | -3.1M | -3.73M | -2.14M | -1.43M |
Interest Income | 527K | 1.69M | 2.36M | 493K | 104K | 664K | 2.71M | 2.06M | 1.14M | 751K |
Interest Expense | 1.02M | 3.31M | 8.48M | 8.59M | 8.38M | 7.27M | 5.81M | 5.78M | 3.28M | 2.19M |
Other Income/Expense | -2.34M | -2.02M | -6.12M | -8.1M | -33.17M | 36.53M | -3.05M | 1.92M | 12.18M | 10.64M |
Pretax Income | -42.21M▲ 0% | -66.74M▼ 58.1% | -94.35M▼ 41.4% | -104.33M▼ 10.6% | -142.6M▼ 36.7% | -44.82M▲ 68.6% | -42.2M▲ 5.9% | -38.51M▲ 8.7% | -26.98M▲ 29.9% | -19.65M▲ 0% |
Pretax Margin % | - | - | -1553.29% | -1639.85% | -1268.73% | -1151.64% | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -42.21M▲ 0% | -66.74M▼ 58.1% | -94.35M▼ 41.4% | -104.33M▼ 10.6% | -142.6M▼ 36.7% | -44.82M▲ 68.6% | -42.2M▲ 5.9% | -38.51M▲ 8.7% | -26.98M▲ 29.9% | -19.65M▲ 0% |
Net Margin % | - | - | -1553.29% | -1639.85% | -1268.73% | -1151.64% | - | - | - | - |
Net Income Growth % | -27.27% | -58.11% | -41.37% | -10.58% | -36.69% | 68.57% | 5.85% | 8.74% | 29.94% | 44.87% |
Net Income (Continuing) | -42.21M | -66.74M | -94.35M | -104.33M | -142.6M | -44.82M | -42.2M | -38.51M | -26.98M | -19.65M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -99.20▲ 0% | -124.73▼ 25.7% | -149.06▼ 19.5% | -99.59▲ 33.2% | -109.35▼ 9.8% | -29.48▲ 73.0% | -17.35▲ 41.1% | -6.98▲ 59.8% | -3.31▲ 52.6% | -2.41▲ 0% |
EPS Growth % | -3.39% | -25.74% | -19.51% | 33.19% | -9.8% | 73.04% | 41.15% | 59.77% | 52.58% | 64.86% |
EPS (Basic) | -99.20 | -124.73 | -149.06 | -99.59 | -109.35 | -29.48 | -17.35 | -6.98 | -3.31 | - |
Diluted Shares Outstanding | 425.5K | 535.08K | 684.2K | 1.05M | 1.3M | 1.52M | 2.43M | 5.52M | 8.15M | 8.15M |
Basic Shares Outstanding | 425.5K | 535.08K | 684.2K | 1.05M | 1.3M | 1.52M | 2.43M | 5.52M | 8.15M | 8.15M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
KALA Balance Sheet
KALA BIO, Inc. (KALA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 115.21M | 177.03M | 105.48M | 171.38M | 124.37M | 85.94M | 52.87M | 52.8M | 9.49M | 12.32M |
Cash & Short-Term Investments | 114.56M | 170.9M | 85.45M | 153.54M | 92.14M | 70.5M | 50.9M | 51.18M | 7.56M | 8.76M |
Cash Only | 114.56M | 170.9M | 85.45M | 77.26M | 92.14M | 70.5M | 50.9M | 51.18M | 7.56M | 1.76M |
Short-Term Investments | 0 | 0 | 0 | 76.28M | 0 | 0 | 0 | 0 | 0 | 7M |
Accounts Receivable | 0 | 1.03M | 13.1M | 9.85M | 17.45M | 6.5M | 236K | 0 | 0 | 74K |
Days Sales Outstanding | - | - | 787.09 | 565.34 | 566.82 | 609.3 | - | - | - | - |
Inventory | 0 | 4.09M | 4.65M | 5.23M | 8.64M | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | 1.57K | 595.69 | 601.51 | 769.64 | - | - | - | - | - |
Other Current Assets | 648K | 477K | 1.38M | 1.55M | 3.92M | 8.25M | 1.18M | 1.62M | 1.93M | 3.48M |
Total Non-Current Assets | 920K | 43.94M | 48.84M | 50.23M | 15.06M | 878K | 3.08M | 2.69M | 0 | 0 |
Property, Plant & Equipment | 786K | 31.73M | 32.48M | 31.02M | 4.02M | 416K | 2.78M | 2.44M | 0 | 0 |
Fixed Asset Turnover | - | - | 0.19x | 0.21x | 2.80x | 9.36x | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 134K | 12.21M | 12.58M | 0 | 0 | 462K | 0 | 246K | 0 | 144K |
Other Non-Current Assets | 0 | 0 | 3.78M | 19.21M | 11.04M | 0 | 301K | 0 | 0 | 0 |
Total Assets | 116.13M▲ 0% | 220.97M▲ 90.3% | 154.32M▼ 30.2% | 221.61M▲ 43.6% | 139.43M▼ 37.1% | 86.82M▼ 37.7% | 55.95M▼ 35.6% | 55.48M▼ 0.8% | 9.49M▼ 82.9% | 12.32M▲ 0% |
Asset Turnover | - | - | 0.04x | 0.03x | 0.08x | 0.04x | - | - | - | 0.00x |
Asset Growth % | 150.67% | 90.27% | -30.16% | 43.6% | -37.08% | -37.73% | -35.56% | -0.83% | -82.9% | -252.58% |
Total Current Liabilities | 14.46M | 17.01M | 24.77M | 22.23M | 37.42M | 25.68M | 8.35M | 16.96M | 2.49M | 1.56M |
Accounts Payable | 1.2M | 5.45M | 2.52M | 1.72M | 4.9M | 2.35M | 919K | 628K | 986K | 1.04M |
Days Payables Outstanding | 682.32 | 2.08K | 322.71 | 198.32 | 436.45 | 334.92 | 1.11K | 885.02 | - | 6.09K |
Short-Term Debt | 6.67M | 463K | 1.33M | 0 | 0 | 5M | 0 | 10.34M | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 4.19M | 1.07M | 637K | 0 | 0 |
Other Current Liabilities | 3.79M | 5.92M | 13.1M | 9.29M | 17.15M | 10.8M | 2.62M | 2.39M | 1.51M | 513K |
Current Ratio | 7.97x | 10.41x | 4.26x | 7.71x | 3.32x | 3.35x | 6.33x | 3.11x | 3.81x | 7.91x |
Quick Ratio | 7.97x | 10.17x | 4.07x | 7.48x | 3.09x | 3.35x | 6.33x | 3.11x | 3.81x | 7.91x |
Cash Conversion Cycle | - | - | 1.06K | 968.53 | 900.02 | - | - | - | - | - |
Total Non-Current Liabilities | 12M | 98.98M | 99.86M | 99.39M | 85.2M | 42.16M | 40.1M | 26.2M | 0 | 0 |
Long-Term Debt | 11.99M | 70.23M | 71.18M | 72.24M | 78.93M | 37.94M | 34.19M | 20.1M | 0 | 0 |
Capital Lease Obligations | 0 | 28.75M | 28.67M | 27.14M | 548K | 0 | 1.8M | 1.43M | 0 | 2.34M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9K | 0 | 0 | 0 | 5.72M | 4.22M | 4.11M | 4.66M | 0 | 0 |
Total Liabilities | 26.45M | 115.98M | 124.63M | 121.61M | 122.62M | 67.85M | 48.45M | 43.15M | 2.49M | 1.56M |
Total Debt | 18.65M | 99.44M | 101.18M | 100.92M | 80.19M | 42.95M | 36.32M | 32.25M | 0 | 0 |
Net Debt | -95.91M | -71.46M | 15.73M | 23.65M | -11.95M | -27.55M | -14.57M | -18.93M | -7.56M | -1.76M |
Debt / Equity | 0.21x | 0.95x | 3.41x | 1.01x | 4.77x | 2.26x | 4.84x | 2.62x | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.06x |
Interest Coverage | -39.13x | -19.53x | -10.40x | -11.20x | -13.06x | -11.20x | -6.73x | -6.99x | -7.24x | -13.14x |
Total Equity | 89.68M▲ 0% | 104.99M▲ 17.1% | 29.69M▼ 71.7% | 100M▲ 236.8% | 16.8M▼ 83.2% | 18.97M▲ 12.9% | 7.5M▼ 60.5% | 12.33M▲ 64.3% | 7M▼ 43.3% | 10.76M▲ 0% |
Equity Growth % | 202.18% | 17.07% | -71.72% | 236.77% | -83.2% | 12.91% | -60.45% | 64.34% | -43.27% | -304.45% |
Book Value per Share | 210.76 | 196.21 | 43.40 | 95.46 | 12.89 | 12.48 | 3.09 | 2.23 | 0.86 | 1.32 |
Total Shareholders' Equity | 89.68M | 104.99M | 29.69M | 100M | 16.8M | 18.97M | 7.5M | 12.33M | 7M | 10.76M |
Common Stock | 25K | 34K | 36K | 59K | 1K | 2K | 3K | 6K | 28K | 19K |
Retained Earnings | -134.37M | -201.11M | -295.46M | -399.78M | -542.39M | -587.21M | -629.41M | -667.92M | -694.9M | -696.52M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.54M | -1.82M | 0 | 4K | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KALA Cash Flow Statement
KALA BIO, Inc. (KALA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -34.1M | -54.12M | -92.72M | -90.69M | -108.23M | -78.91M | -27.93M | -29.38M | -31.99M | -26.06M |
Operating CF Margin % | - | - | -1526.51% | -1425.56% | -962.94% | -2027.44% | - | - | - | - |
Operating CF Growth % | -24.68% | -58.72% | -71.32% | 2.19% | -19.34% | 27.1% | 64.61% | -5.21% | -8.88% | -46.02% |
Net Income | -42.21M | -66.74M | -94.35M | -104.33M | -142.6M | -44.82M | -42.2M | -38.51M | -26.98M | -19.65M |
Depreciation & Amortization | 287K | 955K | 843K | 912K | 975K | 537K | 303K | 259K | 317K | 249K |
Stock-Based Compensation | 3.57M | 8.62M | 9.99M | 13.31M | 16.09M | 7.01M | 7.46M | 8.39M | 7M | 4.21M |
Deferred Taxes | 1.84M | 390K | 0 | -5K | 5.42M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 111K | 274K | 2.73M | 2.99M | 22.51M | -42.12M | -2.39M | 2.26M | -6.8M | -5.34M |
Working Capital Changes | 2.3M | 2.38M | -11.94M | -3.57M | -10.62M | 491K | 8.89M | -1.78M | -5.52M | -5.53M |
Change in Receivables | 0 | -157.85M | -11.56M | 1.96M | -5.76M | 15.14M | 78K | 0 | 0 | 0 |
Change in Inventory | 0 | -3.87M | -4.27M | -2.37M | -6.26M | 1.71M | 7.54M | 0 | 0 | 0 |
Change in Payables | 205K | 4.09M | -2.77M | -924K | 3.23M | -2.08M | -1.9M | -291K | 358K | 113K |
Cash from Investing | -480K | -1.58M | -1.33M | -78.21M | 70.8M | 62.72M | -429K | -208K | -15K | -7.03M |
Capital Expenditures | -480K | -1.58M | -1.33M | -1.94M | -886K | -313K | -610K | -208K | -15K | -16K |
CapEx % of Revenue | - | - | 21.98% | 30.53% | 7.88% | 8.04% | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 2.07M | -4.65M | 62.91M | 47K | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -2.07M | 92K | 114K | 0 | 0 | 0 | -15K |
Cash from Financing | 103.7M | 124.1M | 8.98M | 160.63M | 42.55M | -7.94M | 8.51M | 29.88M | -11.62M | -7.38M |
Debt Issued (Net) | 8.89M | 52.81M | -30K | -32K | -263K | -40.04M | -10M | -5.04M | -22.5M | -22.54M |
Equity Issued (Net) | 94M | 70.77M | 8.43M | 158.56M | 41.23M | 31.8M | 20.5M | 34.96M | 10.89M | 15.1M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 802K | 530K | 587K | 2.1M | 1.58M | 301K | -2M | -42K | 0 | 58K |
Net Change in Cash | 69.12M▲ 0% | 68.41M▼ 1.0% | -85.07M▼ 224.4% | -8.28M▲ 90.3% | 5.12M▲ 161.9% | -24.13M▼ 571.2% | -19.85M▲ 17.7% | 286K▲ 101.4% | -43.62M▼ 15353.1% | -40.46M▲ 0% |
Free Cash Flow | -34.58M▲ 0% | -55.7M▼ 61.1% | -94.06M▼ 68.9% | -92.64M▲ 1.5% | -109.12M▼ 17.8% | -79.22M▲ 27.4% | -28.54M▲ 64.0% | -29.59M▼ 3.7% | -31.99M▼ 8.1% | -26.06M▲ 0% |
FCF Margin % | - | - | -1548.49% | -1456.08% | -970.83% | -2035.48% | - | - | - | - |
FCF Growth % | -25.73% | -61.08% | -68.86% | 1.51% | -17.8% | 27.4% | 63.98% | -3.69% | -8.11% | 4.95% |
FCF per Share | -81.26 | -104.10 | -137.47 | -88.43 | -83.68 | -52.10 | -11.73 | -5.36 | -3.93 | -3.20 |
FCF Conversion (FCF/Net Income) | 0.81x | 0.81x | 0.98x | 0.87x | 0.76x | 1.76x | 0.66x | 0.76x | 1.19x | 1.33x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KALA Key Ratios
KALA BIO, Inc. (KALA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -4403.86% | -68.57% | -140.11% | -160.89% | -244.19% | -250.56% | -318.75% | -388.29% | -279.18% | -1335.64% |
Return on Invested Capital (ROIC) | - | -355.64% | -167.61% | -85.37% | -127.74% | - | - | - | - | -2014.23% |
Gross Margin | - | - | 53.11% | 50.13% | 63.55% | 34.22% | - | - | - | - |
Net Margin | - | - | -1553.29% | -1639.85% | -1268.73% | -1151.64% | - | - | - | - |
Debt / Equity | 0.21x | 0.95x | 3.41x | 1.01x | 4.77x | 2.26x | 4.84x | 2.62x | - | 0.00x |
Interest Coverage | -39.13x | -19.53x | -10.40x | -11.20x | -13.06x | -11.20x | -6.73x | -6.99x | -7.24x | -13.14x |
FCF Conversion | 0.81x | 0.81x | 0.98x | 0.87x | 0.76x | 1.76x | 0.66x | 0.76x | 1.19x | 1.33x |
Revenue Growth | - | - | - | 4.74% | 76.67% | -65.37% | -100% | - | - | - |
Related:KALA Dividend History·KALA Revenue History·KALA Price History·KALA P/E History·KALA Financial Ratios·KALA Institutional Holders
KALA SEC Filings & Documents
KALA BIO, Inc. (KALA) SEC filings — annual & quarterly reports (10-K, 10-Q)
KALA Frequently Asked Questions
KALA BIO, Inc. (KALA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
KALA BIO, Inc. (KALA) grew revenue by 0.0% over the past year. Growth has been modest.
KALA BIO, Inc. (KALA) reported a net loss of $19.7M for fiscal year 2025.
Dividend & Returns
KALA BIO, Inc. (KALA) has a return on equity (ROE) of -279.2%. Negative ROE indicates the company is unprofitable.
KALA BIO, Inc. (KALA) had negative free cash flow of $26.1M in fiscal year 2025, likely due to heavy capital investments.